1. Clinical & Scientific Overview
Escitalopram Oxalate (TIP-MED-000206, Reference Code [11.2]) is classified under
CNS & Psychiatric Medicines (Ch 11) as a Selective Serotonin Reuptake Inhibitor (S-Enantiomer of Citalopram—Most Selective SSRI).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • NLEM 2022 Core Essential Medicine.
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.2], p. 140): Nexito (Sun Pharma), Cipralex (Lundbeck), Stalopam (Lupin), Feliz-S (Torrent), Rexipra (Intas); In FDC with Clonazepam (Short-term only!): Nexito-Plus, Stalopam-Plus — Strengths & Forms: Oral Film-Coated Scored Tablets: 5 mg, 10 mg, 15 mg, 20 mg
Oral Film-Coated Scored Tablets: 5 mg, 10 mg, 15 mg, 20 mg
3. Mechanism of Action & Pharmacodynamics
Pure active S-(+)-enantiomer of racemic Citalopram; binds with highest selectivity among all SSRIs to both the primary orthosteric site and an allosteric modulatory site on the presynaptic Serotonin Transporter (SERT / SLC6A4), blocking 5-HT reuptake into presynaptic neurons. Chronic elevation of synaptic 5-HT downregulates somatodendritic 5-HT1A autoreceptors and stimulates hippocampal BDNF neuroplasticity over 2–4 weeks.
4. Therapeutic Indications & Evidence-Supported Uses
- Major Depressive Disorder (MDD)
- Generalized Anxiety Disorder (GAD), Panic Disorder, Social Anxiety Disorder, and Obsessive-Compulsive Disorder (OCD)
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adults: Start 10 mg orally once daily; may increase after >=1 week to maximum 20 mg once daily. Elderly (>65 yr), hepatic impairment, or CYP2C19 poor metabolizers: Strict maximum 10 mg once daily (due to QTc prolongation risk).
Administration & Meal Timing: Oral; once daily in the morning or evening, with or without food.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Maximum 10 mg once daily in mild-to-moderate hepatic impairment.
No adjustment in mild-to-moderate renal impairment; use caution in CrCl < 20 mL/min.
Maximum 10 mg once daily in mild-to-moderate hepatic impairment.
7. Contraindications, Precautions & High-Risk Warnings
- Concomitant MAO Inhibitors (Selegiline, Rasagiline, Linezolid) or within 14 days of stopping an MAOI — fatal Serotonin Syndrome
- Known congenital Long QT Syndrome or concomitant QT-prolonging drugs (Pimozide)
Key Clinical Precautions: Maximum 10 mg once daily in mild-to-moderate hepatic impairment.
8. Adverse Effects Profile
- Initial transient nausea, insomnia or somnolence, and increased anxiety during first 1–2 weeks
- Sexual dysfunction (anorgasmia, delayed ejaculation, decreased libido — via 5-HT2A/2C stimulation)
- SIADH-induced hyponatraemia (especially in elderly patients or those on thiazide diuretics)
- Dose-dependent QTc prolongation (max 20 mg/day in adults, 10 mg/day in >65 yr)
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- MAOIs, Linezolid, Tramadol, Triptans, Lithium, St. John's Wort: Serotonin Syndrome (clonus, hyperthermia, agitation, autonomic instability)
- NSAIDs (Diclofenac), Aspirin, Clopidogrel, Warfarin: SSRIs deplete platelet serotonin (5-HT) stores and double the risk of upper GI bleeding
- Omeprazole / Esomeprazole (CYP2C19 inhibitors): increase Escitalopram plasma concentration by ~50%
- QT-prolonging agents (Ondansetron, Macrolides, Antipsychotics): additive dose-dependent QTc prolongation
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Full mood improvement takes 2–4 weeks, although sleep and appetite may improve within the first week — continue taking daily as prescribed.
- Do not stop suddenly; taper gradually over 2–4 weeks to avoid SSRI discontinuation symptoms (dizziness, electric-shock paraesthesia).
- Monitor closely for any worsening mood or suicidal ideation during the first 2–4 weeks in young adults.
Storage, Stability & Dispensing Safeguards: Store below 30°C.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2026) • NLEM 2022 (MoHFW) • CDSCO Approved Prescribing Information
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.